文献速递艾滋病与性传播感染

长效注射卡博特韦/利匹韦林项目的财务影响:真实世界经验

Financial Impact of a Long-Acting Injectable Cabotegravir/Rilpivirine Program: A Real-World Experience.
PubMed 文献 · Clin Infect Dis · 2026-09-01

该回顾性队列研究评估了110名接受长效注射卡博特韦/利匹韦林治疗HIV感染者,发现其年均工作人员时间为7.4小时,高于口服ART模型的3.7小时,且时间调整后项目收入显著更低(P<0.001)。但项目仍财务可行,中位每针收入2163美元,91%注射零自付费用;项目收入损失占4.9%,与Medicaid覆盖、缺乏ADAP覆盖和保险变更相关。

要点

  • 长效注射CAB/RPV所需工作人员时间为口服ART的两倍(7.4 vs 3.7小时/年)。
  • 尽管时间调整后收入较低,项目仍财务可行,中位每针收入2163美元。
  • 支付方构成和保险稳定性对项目可持续性和公平可及至关重要。

核心结论

  • 长效注射CAB/RPV项目需要双倍工作人员时间且时间调整后收入低于口服ART,但通过buy-and-bill模式仍可财务可行。

主要发现

  • LAI CAB/RPV年均每参与者工作人员时间为7.4小时,口服ART模型为3.7小时。
  • 所有研究年份中,LAI CAB/RPV每管理小时的中位年项目收入显著低于口服ART模型(p<0.001)。
  • 中位每针项目收入为2163美元,91%的注射自付费用为0美元。
  • 项目收入损失发生在4.9%的注射中,与Medicaid覆盖、缺乏ADAP覆盖和保险变更相关。

临床怎么用

  • 在资源规划中应考虑LAI CAB/RPV所需增加的员工时间。
  • 需关注支付方构成和保险稳定性以维持项目可持续性和公平可及。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) is an effective HIV treatment, but barriers, such as financial considerations limit implementation. Understanding the real-world financial impact is essential for program sustainability and equitable access. METHODS: This retrospective cohort study at the University of Nebraska Medical Center, Specialty Care Center (May 2022 to December 2024) evaluated people with HIV (PWH) receiving LAI CAB/RPV via buy-and-bill acquisition. We assessed annual staff time, program income (PI), and patient costs (PC). The primary endpoint was annual PI adjusted for staff time per patient compared to a modeled oral antiretroviral therapy (ART) comparator (bictegravir/emtricitabine/tenofovir alafenamide) using Wilcoxon Signed-Rank test. PI and PC were compared across study years and payer mix with Kruskal-Wallis test. Multivariate regression models explored factors predicting PI losses. RESULTS: The study included 110 PWH receiving 862 injections. LAI CAB/RPV required more annual staff time per participant than oral ART (7.4 hours vs. 3.7 hours). Median annual PI per participant hour managed was significantly lower for LAI CAB/RPV versus oral ART model across all study years (p<0.001). Despite this, the LAI program remained financially viable (median PI of $2,163/injection) with minimal PC; 91% of injections had $0 cost-sharing. PI losses occurred in 4.9% of injections and was associated with Medicaid coverage, lack of AIDS Drug Assistance Program (ADAP) coverage, and insurance changes. CONCLUSIONS: Although LAI CAB/RPV requires double the staff time and generates less time-adjusted PI than oral ART, buy-and-bill LAI programs can remain financially viable. Payer mix and insurance stability are essential to ensuring sustainability and equitable access.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Havens JP, O'Neill J, Kubat M, et al. Financial Impact of a Long-Acting Injectable Cabotegravir/Rilpivirine Program: A Real-World Experience. Clin Infect Dis. 2026. PMID: 42674566. doi:10.1093/cid/ciag537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。